Pathway to Cures

Founder and managing director who launched and leads Pathway to Cures since November 2022. Brings over 35 years of experience commercializing early-stage research and launching science-based venture funds, including founding managing director roles at IU Ventures and ARCH development partners.

Venture principal responsible for investment sourcing, evaluation, and transaction management. Involved in the bleeding disorders community since 2004 with experience in clinic operations, pharmacy management, and pharmaceutical contracting.

Professor of Pediatrics at Nationwide Children's Hospital and Ohio State University, serving as director of pediatric hematology. Leading expert in bleeding disorders with multiple professional affiliations and recognition as Physician of the Year.

Senior vice president responsible for fundraising and development strategy for Pathway to Cures. Brings over 20 years of nonprofit fundraising and management experience.

Hematologist and researcher with extensive academic career at University of North Carolina Chapel Hill and leadership roles at Versiti blood health organization. Expert in hemophilia diagnosis and treatment with numerous faculty and research directorships.

Independent consultant and entrepreneur-in-residence at Third Rock Ventures with 30 years in biotechnology R&D. Senior vice president at Biogen leading hematology and gene therapy programs, and former president of the National Hemophilia Foundation with extensive FDA advisory experience.

Co-founder and Chief Scientific Officer of PointLoma BioSciences with extensive expertise in gene therapy, cell therapy, and genome editing. Contributed to multiple approved and late-stage therapeutic programs including work on hemophilia A and B gene therapies.

Visiting professor at Rockefeller University and board member of Incyte, CRISPR Therapeutics, and Virion Therapeutics. Co-founder of Spark Therapeutics with pioneering research in AAV-mediated gene therapy for hemophilia and membership in the National Academy of Medicine and Sciences.

Internationally respected pediatric hematology leader serving as chief medical and scientific advisor. Professor of Clinical Pediatrics at Yale University School of Medicine with expertise in bleeding and clotting disorders and gene therapy for hemophilia, having participated in over 110 clinical research trials.

Chief financial officer and chief business officer overseeing finance, accounting, and business development. Senior healthcare finance and operations executive with diverse experience in nonprofit finance, pharma/biotech, and academic medical administration.

President and CEO of the National Bleeding Disorders Foundation and board member. Seasoned nonprofit leader who previously served as president and CEO of the Epilepsy Foundation, growing annual revenues from $10 million to $25 million between 2012 and 2020.

Private investor and board chair with personal connection to the bleeding disorders community through his son. Co-founder of Inspiration Biopharmaceutical and Martin Midstream Partners, with experience across multiple nonprofit and for-profit boards.

Strategic leader with 28 years in pharmaceutical medical affairs. Held senior positions at Astellas Pharma, Spark Therapeutics, Baxter/Baxalta/Shire, and Eisai, with focus on patient advocacy and community engagement.

Professor of Pediatrics and Pathology at University of Michigan leading the Pediatric Hemophilia and Coagulation Disorders Program. Active in clinical trials for novel hemophilia therapeutics including gene therapy, with recognition for research leadership in the field.

Independent consultant and adjunct professor specializing in gene therapy development. Pioneered the first approved AAV-based gene therapy for hemophilia A at BioMarin Pharmaceutical, bringing the program from research through regulatory approval with over 25 years of R&D experience.